Tezepelumab
Structural basis for inhibition of TSLP-signaling by Tezepelumab (PDB 5J13)[1] | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | thymic stromal lymphopoietin (TSLP) |
| Clinical data | |
| Trade names | Tezspire |
| Other names | MEDI9929, AMG 157, tezepelumab-ekko |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a622010 |
| License data |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6400H9844N1732O1992S52 |
| Molar mass | 144590.40 g·mol−1 |
Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma.[6][8][9][10] Tezepelumab blocks thymic stromal lymphopoietin (TSLP),[6] an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.[11]
The most common side effects include arthralgia (joint pain) and pharyngitis (sore throat).[8]
Tezepelumab was approved for medical use in the United States in December 2021,[6][12][7] and in the European Union in September 2022.[8][13] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[14]
- ^ Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1) 14937. Bibcode:2017NatCo...814937V. doi:10.1038/ncomms14937. PMC 5382266. PMID 28368013.
- ^ "Tezspire (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 16 April 2025. Retrieved 3 May 2025.
- ^ "Tezspire Product information". Health Canada. 25 April 2012. Archived from the original on 1 October 2022. Retrieved 1 October 2022.
- ^ "Summary Basis of Decision - Tezspire". Health Canada. 23 October 2014. Archived from the original on 24 January 2023. Retrieved 24 January 2023.
- ^ "Details for: Tezspire". Health Canada. 19 October 2022. Retrieved 3 March 2024.
- ^ a b c d "Tezspire- tezepelumab-ekko injection, solution". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.
- ^ a b "Tezspire (tezepelumab) approved in the US for severe asthma". AstraZeneca (Press release). 17 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021.
- ^ a b c d Cite error: The named reference
Tezspire EPARwas invoked but never defined (see the help page). - ^ Marone G, Spadaro G, Braile M, Poto R, Criscuolo G, Pahima H, et al. (November 2019). "Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma". Expert Opinion on Investigational Drugs. 28 (11): 931–940. doi:10.1080/13543784.2019.1672657. PMID 31549891. S2CID 202746054.
- ^ Matera MG, Rogliani P, Calzetta L, Cazzola M (February 2020). "TSLP Inhibitors for Asthma: Current Status and Future Prospects". Drugs. 80 (5): 449–458. doi:10.1007/s40265-020-01273-4. PMID 32078149. S2CID 211194472.
- ^ "Tezepelumab granted Breakthrough Therapy Designation by US FDA". AstraZeneca (Press release). 7 September 2018. Archived from the original on 10 September 2018. Retrieved 10 September 2018.
- ^ "Drug Trials Snapshots: Tezspire". U.S. Food and Drug Administration (FDA). 17 December 2021. Archived from the original on 28 July 2023. Retrieved 28 July 2023. This article incorporates text from this source, which is in the public domain.
- ^ "Tezspire approved in the EU for the treatment of severe asthma" (Press release). AstraZeneca. 21 September 2022. Archived from the original on 22 September 2022. Retrieved 21 September 2022.
- ^ Advancing Health Through Innovation: New Drug Therapy Approvals 2021. U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original (PDF) on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.